Why MakeMyTrip Stock Fell 13.2% Last Month

What happened Shares of MakeMyTrip (NASDAQ: MMYT) dipped 13.2% in April, according to data from S&P Global Market Intelligence. India faced surging COVID-19 infections and deaths, and it’s not surprising

  Read more »

Is Generic-Drug Maker Viatris a Keeper?

In this video from Motley Fool Live, recorded on April 5, Fool.com Contributors Brian Orelli and Keith Speights discuss a question from a member named Angel, who asks whether Viatris

  Read more »

Clearance? Approval? What Should Investors Make of Nano-X’s FDA Decision?

Last month, Nano-X Imaging (NASDAQ: NNOX) gained 501(k) clearance from the Food and Drug Administration (FDA) for its X-ray device. In this video from Motley Fool Live, recorded on April

  Read more »

Why Shares of Chart Industries Climbed 13% in April

What happened Falling more than 9% through the first three weeks of April, shares of Chart Industries (NYSE: GTLS) weren’t giving investors much to celebrate — especially since the S&P

  Read more »

Some Prominent Doctors Continue to Shun Biogen’s Alzheimer’s Drug

Biogen (NASDAQ: BIIB) will get a decision on Alzheimer’s disease drug aducanumab next month, but a recent op-ed by members of the Food and Drug Administration (FDA) advisory committee that

  Read more »

Is Vaccine Maker Vaxart Worth Holding From Here?

Shares of vaccine expert Vaxart (NASDAQ: VXRT) have gone on a wild ride over the past 12 months as the company has released data for its coronavirus vaccine. In this

  Read more »